In the BioHarmony Drug Report Database

"Preview" Icon

Rucaparib camsylate

Rubraca (rucaparib camsylate) is a small molecule pharmaceutical. Rucaparib camsylate was first approved as Rubraca on 2016-12-19. It is used to treat ovarian neoplasms in the USA. It has been approved in Europe to treat ovarian neoplasms. It is known to target poly [ADP-ribose] polymerase 1. Rubraca’s patents are valid until 2035-08-17 (FDA).

 

Trade Name

 

Rubraca
 

Common Name

 

rucaparib camsylate
 

ChEMBL ID

 

CHEMBL3833368
 

Indication

 

ovarian neoplasms
 

Drug Class

 

Poly-ADP-ribose polymerase inhibitors

Image (chem structure or protein)

Rucaparib camsylate structure rendering